Date: Monday, October 22, 2018
Session Title: Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity
Session Type: ACR Poster Session B
Session Time: 9:00AM-11:00AM
Recent studies comparing JAK-inhibitors (Jak-i) and adalimumab seem to show a better efficacy of JAK-i on patient-reported outcomes in rheumatoid arthritis (RA). As there is no study comparing directly the JAK-i with other biologic DMARDs (bDMARDs), we performed a meta-analysis and compared the effect size of JAK-i and bDMARD versus synthetic DMARDs (sDMARDs) on quality of life
We performed a systematic review of the literature until May 2018 using database including : MEDLINE (via PUBMED), EMBASE and abstracts from the ACR and EULAR congresses 2015-2017. We selected all randomized controlled trials (RCT) comparing quality of life (evaluated by SF36) in patient with rheumatoid arthritis treated with bDMARD or JAK-i versus sDMARDs. We performed meta-analysis comparing the effect size of JAK-i (versus sDMARDs) and bDMARD (versus sDMARDs) on PCS SF36 and MCS SF36 at 12 weeks
Statistical analysis determined in each study effect size.
Pooled ES were computed by meta-analysis. Data were analyzed using the inverse variance approach.
The literature search identified240 articles plus one found by manuel search and no congress abstract. Finally, 44 articles met the inclusion criteria.
JAK-i and bDMARD showed higher level of quality of life than sDMARDs. The results concerning the meta-analysis comparing the effect size are:
- For the SF36 PCS at 12 weeks: JAK-i: +4,82 IC95% [3,88, 5.77] and bDMARDs : +3,99 IC95% [2,81, 5,18]
- For the SF36 MCS a 12 weeks: JAK-i: +3,42 IC95% [2.24, 4,60] and bDMARD: 2,99 IC95% [2.02, 3.96]
The range of the confidence intervals seems similar between JAK-I and bDMARDs.
SF36 PCS at 12 weeks:
-Results for JAK-i:
In this meta-analysis, JAK-inhibitor and bDMARD showed better SF36 PCS and MCS at 12 weeks in comparison with sDMARDs.
The range of the confidence intervals seems similar between JAK-I and bDMARDs, suggesting a similar efficiency on the components of the SF36.
More head-to-head studies are needed to draw definitive conclusions on potential efficacy differences between JAK-inhibitor and bDMARDs in RA.
To cite this abstract in AMA style:Boudhabhay M, Barnetche T, Vergne-Salle P. Effect of JAK-Inhibitor Versus Bdmards on Quality of Life in Rheumatoid Arthritis : A Meta Analysis of Randomized Controlled Trials [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/effect-of-jak-inhibitor-versus-bdmards-on-quality-of-life-in-rheumatoid-arthritis-a-meta-analysis-of-randomized-controlled-trials/. Accessed June 1, 2023.
« Back to 2018 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-jak-inhibitor-versus-bdmards-on-quality-of-life-in-rheumatoid-arthritis-a-meta-analysis-of-randomized-controlled-trials/